2.03

12.15% 0.22

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.03, with a volume of 15.79M. It is up +12.15% in the last 24 hours and up +87.96% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$1.81

Open:

$2.14

24h Volume:

15.79M

Relative Volume:

12.22

Market Cap:

$103.00M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.2229

EPS:

-1.66

Net Cash Flow:

$-54.24M

1W Performance:

+70.59%

1M Performance:

+87.96%

6M Performance:

-33.00%

1Y Performance:

-83.91%

1-Day Range:

$1.65

$2.16

1-Week Range:

$1.24

$2.16

52-Week Range:

$0.9857

$13.50

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

164

Twitter

@CabalettaBio

Next Earnings Date

2025-03-31

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	2.03	60.38M	0	-67.68M	-54.24M	-1.66
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

02:23 AM

Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - Defense World

02:23 AM

May 16, 2025

Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

CABA Stock News: Citigroup Lowers Price Target but Maintains Buy - GuruFocus

May 16, 2025

CABA: Guggenheim Raises Price Target for Cabaletta Bio to $25 | CABA Stock News - GuruFocus

May 16, 2025

UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating - marketscreener.com

May 16, 2025

Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating - TipRanks

May 16, 2025

Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rating | CABA Stock News - GuruFocus

May 16, 2025

Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission - marketscreener.com

May 16, 2025

41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Stifel Financial Corp - Defense World

May 16, 2025

Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday - MarketBeat

May 16, 2025

May 15, 2025

Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Asianet Newsable

May 15, 2025

Fred Alger Management LLC Sells 1,803,170 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

May 15, 2025

CABA: Guggenheim Raises Price Target to $25, Maintains Buy Ratin - GuruFocus

May 15, 2025

CABA: Guggenheim Raises Price Target to $25, Maintains Buy Rating | CABA Stock News - GuruFocus

May 15, 2025

Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $2 - GuruFocus

May 15, 2025

Cabaletta Bio (CABA) Targets 2027 for Rese-cel BLA Submission | - GuruFocus

May 15, 2025